Sana biotechnology obtains a non-exclusive license to crispr cas12b gene editing technology from beam therapeutics to enable engineered cell programs

Agreement combines beam's gene editing technology with sana's ex vivo platform

SANA Ratings Summary

SANA Quant Ranking